Last updated: 2026-10-02 22:15:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
BioCardia, Inc. (BCDA) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $1.05, with a market capitalization of $15.29M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.75 to $1.80. This page covers its latest market performance, valuation, price trends and company information.
$15.29M | |
$1.04 | |
$129.00 | |
$0.75 | |
$1.02 | |
51.20K | |
320.14K | |
-- | |
$1.80 | |
$0.75 | |
-- | |
-- |
BioCardia, Inc. (BCDA) is trading at $1.05 in after-hours trading as of 2026-10-02 20:11:00, up 2.45% ($0.02) from the regular-session close of $1.02.
After-hours trading shows how investors are pricing BCDA after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, BioCardia, Inc. (BCDA) moved from $1.05 to $1.05, representing a decline of 0.48% ($0.01).
The stock traded between $0.99 and $1.11 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 128.52 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 28.1%
BCDA is currently trading at $1.05, placing it 28.1% of the way from its 52-week low of $0.75 to its 52-week high of $1.80. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 21 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of BioCardia, Inc. (BCDA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.